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 Is a device used in this study? 
 If yes: 
◦ Is it approved? 
◦ Is it exempt? 
◦ What is the risk? 
 SR/NSR determination 
• The practice of medicine 
– A class of activities designed solely to enhance the 
well being of an individual patient. 
– Not monitored by the IRB 
– Off label use of an approved device not subject to 
IRB oversight. 
• The conduct of research 
– a class of activities designed to develop or 
contribute to generalizable knowledge. 
– Different set of duties and obligations 
– Subject to IRB review and federal regulatory 
guidelines 
• A medical device is an instrument, apparatus, 
implement, machine, contrivance, implant, in vitro 
reagent, or other similar or related article, including 
any component, part, or accessory, which is—  
–  recognized in the official National Formulary, or the United 
States Pharmacopeia, or any supplement to them,  
– intended for use in the diagnosis of disease or other 
conditions, or in the cure, mitigation, treatment, or 
prevention of disease, in man or other animals, or  
–  intended to affect the structure or any function of the body 
of man or other animals, and  
• which does not achieve its primary intended purposes 
through chemical action within or on the body of man 
or other animals and which is not dependent upon 
being metabolized for the achievement of its primary 
intended purposes (21 U.S.C. 321(h)).  
 
 If you are using the device in a clinical 
investigation, it is by definition 
investigational. 
◦ That does not mean it always needs an IDE 
 Might be exempt 
 Might be NSR (subject to abbreviated requirements) 
All Device 
Investigations 
Subject to 
IDE 
regulations 
Significant Risk (SR): 
Full IDE Requirements 
Non-significant Risk 
(NSR) 
Abbreviated IDE 
Requirements 
Exempt from 
IDE 
Regulations 
 Practice of Medicine 
◦ Off label therapeutic use within the practitioner-
patient relationship 
 Basic Physiologic Research 
◦ Investigating a physiologic principle 
◦ No intent to develop for marketing 
◦ Only using to address the research question, not 
safety and effectiveness 
 Is it being used within its approved indication 
◦ Is the device modified at all? 
◦ How is it being used in the study? 
◦ What is on the PMA or 510(k) approval and how 
does that compare to the use you are proposing in 
your study 
◦ Does the use of the device in this study add risk to 
the subject? 
•  A diagnostic device, if the sponsor complies 
with applicable requirements in 809.10(c) and 
if the testing: 
– Is noninvasive, 
– Does not require an invasive sampling procedure 
that presents significant risk, 
– Does not by design or intention introduce energy 
into a subject, and 
– Is not used as a diagnostic procedure without 
confirmation of the diagnosis by another, medically 
established diagnostic product or procedure. 
 
 A device undergoing consumer preference 
testing, testing of a modification, or testing 
of a combination of two or more devices in 
commercial distribution, if the testing is not 
for the purpose of determining safety or 
effectiveness and does not put subjects at 
risk. 
 Studies to support marketing application 
 Studies that will be submitted to the FDA 
 Studies of new indications 
• IRB must determine if: 
– Significant Risk: requires application to the FDA and 
assignment of IDE #, FDA reporting and monitoring 
requirements 
– Non-significant risk:  abbreviated IDE requirements, 
IRB review, no application to the FDA 
• NOT the same as the FDA class 
• NOT the same as the minimal risk 
determination. 
• Is intended as an implant and presents a potential 
for serious risk to the health, safety, or welfare of a 
subject;  
•  Is purported or represented to be for use 
supporting or sustaining human life and presents a 
potential for serious risk to the health, safety, or 
welfare of a subject;  
• Is for a use of substantial importance in 
diagnosing, curing, mitigating, or treating disease, 
or otherwise preventing impairment of human 
health and presents a potential for serious risk to 
the health, safety, or welfare of a subject; or  
• Otherwise presents a potential for serious risk to 
the health, safety, or welfare of a subject.  
 
 Everything else 
 If previously decided by the FDA, sponsor 
should provide the determination letter. 
 If no previous FDA decision, sponsor makes 
initial determination. 
 IRB must review and either agree or modify 
the sponsor determination if they disagree. 
 FDA is final arbiter if submitted. 
• Review sponsor/PI information. 
• What is the basis for the risk? 
– Proposed use of the device, not the device alone. 
• What is the nature of the harm that may 
result? 
– Potential for serious risk to health, safety or welfare 
• Are there any additional procedures with 
potential for harm? 
– Harm of the procedure should be considered, not 
just the device. 
 Consequences of getting it wrong 
◦ You may have unnecessarily exposed the 
participants to risk. 
◦ Your study may get closed prior to completion. 
◦ You may not be allowed to use the data at all. 
◦ You will be conducting an investigation in violation 
of federal regulatory guidelines and may be subject 
to sanctions by the institution and/or federal 
agencies. 
 
 Emergency use of an unapproved device is 
permissible if: 
◦ The patient has a life-threatening condition that 
needs immediate treatment; 
◦ No generally acceptable alternative treatment for 
the condition exists; and 
◦ Because of the immediate need to use the device, 
here is no time to use existing procedures to get 
FDA approval 
 IRB requirements 
◦ If time, you should submit a Form 11 to the IRB 
before the emergency use.  If not, you must submit 
afterwards 
◦ If possible, informed consent should be obtained. 
◦ Obtain sponsor authorization 
◦ Independent physician assessment. 
 Must be reported to FDA and IRB w/in 5 days 
of use . 
 IRB requires 30 day follow up 
 Appropriate if the investigational device is the 
only option available for a patient with a 
serious or life-threatening condition. 
 Differs from emergency use in that there is 
time to seek prior FDA and IRB approval, 
which is required for it to be used. 
 Specific monitoring and reporting 
requirements apply 
 We are available to help you with this 
process! 
